Headlines
Sanofi exploring vaccine production in Vietnam with local partner
Published by Global Banking & Finance Review®
Posted on May 27, 2025
2 min readLast updated: January 23, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on May 27, 2025
2 min readLast updated: January 23, 2026
Sanofi and VNVC partner to explore vaccine production in Vietnam, with plans for a new plant in Long An, aiming for 100 million doses annually by 2027.
HANOI (Reuters) - French pharmaceutical company Sanofi said on Tuesday it was exploring opportunities for producing vaccines in Vietnam in cooperation with local partner Vietnam Vaccine Company (VNVC), which announced plans to build a new plant.
VNVC launched its plans to set up a plant in the southern province of Long An at a ceremony attended by French President Emmanuel Macron, who was on a visit to Vietnam, and Sanofi officials.
Sanofi and VNVC on Monday signed an agreement on technology transfer.
"The cooperation agreement between Sanofi and Vietnam Vaccine Company aims to explore opportunities for local vaccine production in Vietnam, as part of Sanofi's ongoing commitment to improving vaccine access in the country," Sanofi said in a statement on Tuesday.
The plant is projected to produce 100 million vaccine doses annually for domestic use and export, with operations expected to begin by the end of 2027, VNVC said.
The facility spans 2.6 hectares (6.4 acres) and has received an initial investment of 2 trillion dong ($77.19 million), VNVC said in a statement in response to a query from Reuters, but did not say which vaccines would be produced there.
($1 = 25,911.0000 dong)
(Reporting by Phuong Nguyen; Editing by Martin Petty and Susan Fenton)
The cooperation agreement aims to explore opportunities for local vaccine production in Vietnam, as part of Sanofi's ongoing commitment to improving vaccine access.
The plant is set to be established in the southern province of Long An, Vietnam.
The facility is projected to produce 100 million vaccine doses annually for both domestic use and export.
The facility has received an initial investment of 2 trillion dong, which is approximately $77.19 million.
Operations at the new facility are expected to start by the end of 2027.
Explore more articles in the Headlines category
